Stocklytics Platform
Asset logo for symbol KOD
Kodiak Sciences
KOD48
$9.20arrow_drop_down3.65%-$0.34
Asset logo for symbol KOD
KOD48

$9.20

arrow_drop_down3.65%

Performance History

Chart placeholder
Key Stats
Open$9.46
Prev. Close$9.57
EPS-3.64
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range9.01
9.54
52 Week Range1.37
11.53
Ratios
Revenue-
EBITDA Margin %-
EPS-3.64

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About Kodiak Sciences (KOD)

Kodiak Sciences Inc (KOD) is a biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for the treatment of retinal diseases. The company's lead product candidate, KSI-301, is a novel anti-VEGF (vascular endothelial growth factor) antibody biopolymer conjugate for the treatment of wet age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). KSI-301 has shown promising results in early-stage clinical trials, demonstrating durability and extended dosing intervals compared to existing anti-VEGF therapies. With a market capitalization of approximately $2.5 billion, Kodiak Sciences is well-positioned to advance its pipeline of innovative therapies and address the unmet medical needs in the field of retinal diseases.
In terms of valuation, Kodiak Sciences Inc is currently trading at a PEG ratio of 1.68, indicating a reasonable valuation relative to its earnings growth potential. The company's market cap of $2.5 billion reflects investor confidence in its potential to deliver innovative therapies and capture a significant share of the retinal disease treatment market. Compared to its industry peers, Kodiak Sciences Inc stands out as a promising player, leveraging its proprietary biopolymer conjugate technology platform to develop next-generation therapies with improved efficacy and durability.
Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Victor Perlroth M.D.
Headquarters
Palo Alto
Employees
118
Exchange
NASDAQ
add Kodiak Sciences  to watchlist

Keep an eye on Kodiak Sciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Kodiak Sciences 's (KOD) price per share?

The current price per share for Kodiak Sciences (KOD) is $9.2. The stock has seen a price change of -$0.35 recently, indicating a -3.66% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Kodiak Sciences (KOD)?

For Kodiak Sciences (KOD), the 52-week high is $11.54, which is 25.42% from the current price. The 52-week low is $1.37, the current price is 571.53% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Kodiak Sciences (KOD) a growth stock?

Kodiak Sciences (KOD) has shown an average price growth of -1.65% over the past three years. It has received a score of 75 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Kodiak Sciences as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Kodiak Sciences (KOD) stock price performance year to date (YTD)?

As of the latest data, Kodiak Sciences (KOD) has a year-to-date price change of -7.54%. Over the past month, the stock has experienced a price change of -9.36%. Over the last three months, the change has been 247.17%. Over the past six months, the figure is 273.98%. Looking at a longer horizon, the five-year price change stands at -86.33%.
help

Is Kodiak Sciences (KOD) a profitable company?

Kodiak Sciences (KOD) has a net income of -$260.49M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$277.32M. Furthermore, the EBITDA is -$192.78M.
help

What is the market capitalization of Kodiak Sciences (KOD)?

Kodiak Sciences (KOD) has a market capitalization of $484.14M. The average daily trading volume is 9.22, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level